NEW YORK (GenomeWeb) — Pharmaceutical companies are jockeying to formulate companion diagnostics strategies that involve a new microarray-based assay developed by Almac Diagnostics, according to the company.
NEW YORK (GenomeWeb News) – Almac's diagnostics business today said that it has received a clinical laboratory permit from New York, allowing it to receive clinical samples from the state for clinical testing and trial management.
Almac Diagnostics said this week that a group led by partner Precision Therapeutics has independently validated Almac's ColDx test for stage II colorectal cancer recurrence ahead of its full commercialization in the US.
NEW YORK (GenomeWeb News) – Luminex's board of directors has authorized the firm to repurchase up to the lesser of $22.5 million worth or 900,000 shares of the company's outstanding common stock. The repurchase program is scheduled to expire Dec.
NEW YORK (GenomeWeb News) – Almac Diagnostics said this week that it has launched a next-generation sequencing service to its portfolio, which also includes microarray, qPCR, and immunohistochemical offerings.